Pharmaceutical and Physical Properties of Paclitaxel (Taxol †) Complexes with Cyclodextrins ‡

Sharma, Uma S.; Balasubramanian, Sathyamangalam V.; Straubinger, Robert M.

doi:10.1002/jps.2600841015

Cited by 160 publications

(80 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Paclitaxel (taxol) (TAX), an anticancer agent, whose therapeutic efficacy is limited by its poor aqueous solubility [43] is currently administered in a mixture of Cremophor EL (polyoxyethylated castor oil) and dehydrated ethanol [44] to increase bioavailability. Systemic administration of taxol is associated with several negative side effects in patients including dyspnea, hypotension, broncho-spasm, urticaria, and erythematous rashes [44].…”

Section: Therapeutic Applications Of Polymersomesmentioning

confidence: 99%

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Levine

Ghoroghchian

Freudenberg

et al. 2008

Methods

194

121

View full text Add to dashboard Cite

Nanoparticles are being developed as delivery vehicles for therapeutic pharmaceuticals and contrast imaging agents. Polymersomes (mesoscopic polymer vesicles) possess a number of attractive biomaterial properties that make them ideal for these applications. Synthetic control over block copolymer chemistry enables tunable design of polymersome material properties. The polymersome architecture, with its large hydrophilic reservoir and its thick hydrophobic lamellar membrane, provides significant storage capacity for both water soluble and insoluble substances (such as drugs and imaging probes). Further, the brush-like architecture of the polymersome outer shell can potentially increase biocompatibility and blood circulation times. A further recent advance is the development of multi-functional polymersomes that carry pharmaceuticals and imaging agents simultaneously. The ability to conjugate biologically active ligands to the brush surface provides a further means for targeted therapy and imaging. Hence, polymersomes hold enormous potential as nanostructured biomaterials for future in vivo drug delivery and diagnostic imaging applications.

show abstract

Section: Therapeutic Applications Of Polymersomesmentioning

confidence: 99%

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Levine

Ghoroghchian

Freudenberg

et al. 2008

Methods

194

121

View full text Add to dashboard Cite

show abstract

“…Liposomes (Sharma and Straubinger, 1994), micelles (Onyuksel et al, 1994), polysaccharides (Sharma et al, 1995) and virus vectors (Schreier, 1994) all provide media for administration of drugs. Additionally, micro/nanoparticles prepared from synthetic biodegradable polymers have also been employed (Crotts and Park, 1995;Davis et al, 1996;Sinha et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Encapsulation and release ofα-chymotrypsin from poly(glycerol adipate-co-ω-pentadecalactone) microparticles

Gaskell¹,

Hobbs²,

Rostron³

et al. 2008

Journal of Microencapsulation

View full text Add to dashboard Cite

Polymer based microparticles are increasingly becoming of interest for a variety of applications including drug delivery. Recently poly(glycerol adipate) (PGA) and poly(glycol adipate-co--pentadecalactone) have shown promise for delivery of dexamethasone phosphate and ibuprofen. In this paper the copolyester poly(glycol adipate-co--pentadecalactone) was evaluated as a colloidal delivery system for encapsulated therapeutic proteins. Enzyme containing microparticles were prepared via the double water-in-oil-in-water (w/o/w) emulsion-solvent evaporation methodology. -chymotrypsin was used as a model proteolytic enzyme and its transfer was monitored during the emulsification process, in addition to in vitro release from formed particles. On average 22.1g protein per 1mg polymer was encapsulated, although gradual loss of activity of the protein, once released, was recorded. The work presented shows the potential of this polyester as a delivery system for enzymes via microparticles, with improvements to the system achievable via polymer and process optimisation. The pendant hydroxyl groups on the polymer backbone provide future capacity for tailored alteration of the physical and chemical properties of the polymer, in addition to covalent attachment of various compounds.

show abstract

“…Cyclodextrins (CyD) are complexing agents that can increase the solubility and stability of poorly soluble active substances [35]. Studies have been done on the different types of β-and γ-CyDs.…”

Section: Complexes Of Paclitaxelmentioning

confidence: 99%

“…Today, the formulation on the basis of the inclusion complexes of cyclodextrin and paclitaxel is used [35], most commonly with a paclitaxel to cyclodextrin ratio of 1:10 to 1:150. Different types of cyclodextrins, such as hydroxypropyl-sulphobutyl-7-β-CyD, sulphobutylether-7-β-CyD, acetyl-γ-CyD, hydroxypropyl-β-CyD, hydroxypropyl-γ-CyD, bis(β-CyD), γ-CyD, succinylmethyl-β-CyD, anionic-β-CyD, as well as their mixtures, can be used for making these formulations.…”

Section: Complexes Of Paclitaxelmentioning

confidence: 99%

Paclitaxel as an anticancer agent: isolation, activity, synthesis and stability

et al. 2011

View full text Add to dashboard Cite

AbstractPaclitaxel is isolated from the Pacific yew. It can be obtained from the European yew, but only after chemical modification of the isolated compound by a semi-synthesis procedure. The procedure for total synthesis of paclitaxel is very complicated, involving multiple steps, and the yields of paclitaxel are meagre. This substance is also a metabolite of certain kinds of fungus. The microbiological pathway for producing paclitaxel compared with isolation from plant material involves shorter procuction times but a small yield. Cyclodextrins are usually used for improving the solubility of paclitaxel in aqueous media, with polymeric and other substances added. Paclitaxel has anticancer activity and use for preparing the formulations intravenously administrated to patients with tumors. The paclitaxel concentration in these formulations is determined using validated HPLC methods.

show abstract

Pharmaceutical and Physical Properties of Paclitaxel (Taxol †) Complexes with Cyclodextrins ‡

Cited by 160 publications

References 32 publications

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Encapsulation and release ofα-chymotrypsin from poly(glycerol adipate-co-ω-pentadecalactone) microparticles

Paclitaxel as an anticancer agent: isolation, activity, synthesis and stability

Contact Info

Product

Resources

About